Kamphuis J A M, Linschoten M, Cramer M J, Alsemgeest F, van Kessel D J W, Urgel K, Post M C, Manintveld O C, Hassing H C, Liesting C, Wardeh A J, Olde Bijvank E G M, Schaap J, Stevense-den Boer A M, Doevendans P A, Asselbergs F W, Teske A J
Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht, The Netherlands.
Department of Cardiology, St Jansdal Hospital, Harderwijk, The Netherlands.
Neth Heart J. 2021 May;29(5):288-294. doi: 10.1007/s12471-020-01517-8. Epub 2020 Nov 17.
The relative new subspecialty 'cardio-oncology' was established to meet the growing demand for an interdisciplinary approach to the management of cancer therapy-related cardiovascular adverse events. In recent years, specialised cardio-oncology services have been implemented worldwide, which all strive to improve the cardiovascular health of cancer patients. However, limited data are currently available on the outcomes and experiences of these specialised services, and optimal strategies for cardio-oncological care have not been established.
The ONCOR registry has been created for prospective data collection and evaluation of cardio-oncological care in daily practice.
Dutch hospitals using a standardised cardio-oncology care pathway are included in this national, multicentre, observational cohort study. All patients visiting these cardio-oncology services are eligible for study inclusion. Data collection at baseline consists of the (planned) cancer treatment and the cardiovascular risk profile, which are used to estimate the cardiotoxic risk. Information regarding invasive and noninvasive tests is collected during the time patients receive cardio-oncological care. Outcome data consist of the incidence of cardiovascular complications and major adverse cardiac events, and the impact of these events on the oncological treatment.
Outcomes of the ONCOR registry may aid in gaining more insight into the incidence of cancer therapy-related cardiovascular complications. The registry facilitates research on mechanisms of cardiovascular complications and on diagnostic, prognostic and therapeutic strategies. In addition, it provides a platform for future (interventional) studies. Centres with cardio-oncology services that are interested in contributing to the ONCOR registry are hereby invited to participate.
相对较新的亚专业“心脏肿瘤学”的设立，是为了满足对癌症治疗相关心血管不良事件进行跨学科管理的日益增长的需求。近年来，专门的心脏肿瘤学服务已在全球范围内实施，所有这些服务都致力于改善癌症患者的心血管健康。然而，目前关于这些专门服务的结果和经验的数据有限，并且尚未确立心脏肿瘤学护理的最佳策略。
创建ONCOR登记处，用于前瞻性收集和评估日常实践中的心脏肿瘤学护理。
本项全国性、多中心、观察性队列研究纳入了采用标准化心脏肿瘤学护理路径的荷兰医院。所有就诊于这些心脏肿瘤学服务的患者均符合研究纳入标准。基线数据收集包括（计划中的）癌症治疗和心血管风险概况，用于估计心脏毒性风险。在患者接受心脏肿瘤学护理期间收集有关侵入性和非侵入性检查的信息。结局数据包括心血管并发症和主要不良心脏事件的发生率，以及这些事件对肿瘤治疗的影响。
ONCOR登记处的结果可能有助于更深入地了解癌症治疗相关心血管并发症的发生率。该登记处有助于对心血管并发症的机制以及诊断、预后和治疗策略进行研究。此外，它为未来的（干预性）研究提供了一个平台。特此邀请提供心脏肿瘤学服务且有兴趣为ONCOR登记处做出贡献的中心参与。
